Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE + PD-1 knockout T cells in advanced HCC
NCT04417764Phase 1Unknown
- Sponsor
- Central South University
- Start
- Jun 2019
- Primary completion
- Dec 2024
- Modality
- CRISPR-Cas9, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PD-1 knockout engineered T cells in hepatocellular carcinoma (HCC), sponsored by Central South University. Primary endpoint: Incidence of Adverse Events up to 2 years. Status: unknown.
02
Drugs
PD-1 knockout engineered T cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04417764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04417764.